It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The role of microbiota in health and diseases is being highlighted by numerous studies since its discovery. Depending on the localized regions, microbiota can be classified into gut, oral, respiratory, and skin microbiota. The microbial communities are in symbiosis with the host, contributing to homeostasis and regulating immune function. However, microbiota dysbiosis can lead to dysregulation of bodily functions and diseases including cardiovascular diseases (CVDs), cancers, respiratory diseases, etc. In this review, we discuss the current knowledge of how microbiota links to host health or pathogenesis. We first summarize the research of microbiota in healthy conditions, including the gut-brain axis, colonization resistance and immune modulation. Then, we highlight the pathogenesis of microbiota dysbiosis in disease development and progression, primarily associated with dysregulation of community composition, modulation of host immune response, and induction of chronic inflammation. Finally, we introduce the clinical approaches that utilize microbiota for disease treatment, such as microbiota modulation and fecal microbial transplantation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 The First Affiliated Hospital of Medical College of Shantou University, Department of Endocrine and Metabolic Diseases, Longhu Hospital, Shantou, China (GRID:grid.411679.c) (ISNI:0000 0004 0605 3373)
2 St. John’s University, Department of Pharmaceutical Sciences, Institute for Biotechnology, College of Pharmacy and Health Sciences, Queens, USA (GRID:grid.264091.8) (ISNI:0000 0001 1954 7928)
3 Microbiome Research Center, Moon (Guangzhou) Biotech Ltd, Guangzhou, China (GRID:grid.264091.8)
4 Weifang Medical University, School of Pharmacy, Weifang, China (GRID:grid.268079.2) (ISNI:0000 0004 1790 6079)
5 The Second Affiliated Hospital of Medical College of Shantou University, Department of Cardiovascular, Shantou, China (GRID:grid.411679.c) (ISNI:0000 0004 0605 3373)